NeuroBo Pharma (NRBO) Market Value to Book Value Ratio
NeuroBo Pharmaceuticals relies entirely on external contractors (CROs and CMOs) for drug development. The price-to-book value trend on GURU.Markets shows that this metric equals 1.60. The success of NRBO depends on FDA approval and new investments. The company is currently accelerating the expansion of its obesity drug pipeline for subsequent global market launch.
NeuroBo Pharmaceuticals Inc (NRBO) - metric breakdowns and financial figures
- market value and analyst target forecast:
- market capitalization details:
- book capitalization data:
- debt and solvency information:
Comprehensive company analysis:NeuroBo Pharmaceuticals
This indicator reflects the premium of the company's market value over its net assets amid inflationary pressure. The calculation is based on dividing market capitalization by book value, measuring the efficiency of resource capitalization. Analyzing the market-to-book ratio allows for the identification of business revaluation trends. The growth of this metric for NeuroBo Pharmaceuticals (NRBO) is driven by a shift in focus toward high-yield developments in the field of metabolic diseases. Such strategic portfolio diversification directly increases the investment attractiveness of the assets.
Key competitors
Biogen Inc. (BIIB) - Market Value to Book Value Ratio|Market-to-Book Ratio neurocrine.com (NBIX)|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited|Capitalization to Book Value Ratio AXSM (Axsome)|Market Capitalization to Book Value Ratio ACAD|XENE - Market-to-Book Ratio|Viking Therapeutics - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio supernus.com SUPN|CPRX - Market Value to Book Value Ratio|Market Value to Book Value DNLI (Denali)|Harmony Pharma (HRMY) - Market Value to Book Value Ratio|Market-to-Book Ratio Biohaven Corp (BHVN)|Market Value to Book Value Ratio Amylyx Pharmaceuticals|Capitalization to Book Value Ratio TRVI (trevitherapeutics.com)|Market Capitalization to Book Value Ratio PRAX|AVXL - Market-to-Book Ratio|CeriBell Corp - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio Prothena PRTA|ALEC - Market Value to Book Value Ratio|Market Value to Book Value ANNX (annexonbio.com)|omeros.com (OMER) - Market Value to Book Value Ratio|Market-to-Book Ratio Neurogene Inc (NGNE)|ACIU (AC Immune Corp) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio VYGR|Market Value to Book Value Ratio Neumora Therapeutics (NMRA)|SCLX - Market-to-Book Ratio|Tevogen Bio - Market Cap to Net Assets Ratio|Market Value to Book Value ACOG|CGTX - Market Value to Book Value Ratio|Market Capitalization to Net Assets IKT|SAVA: Market Capitalization to Book Value Ratio|Assertio - Market Value to Book Value|COYA (Coya Therapeutics Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio VistaGen Therapeutics Inc|Market Value to Book Value Ratio Ovid Therapeutics Inc. (OVID)|ABOS (Acumen Pharmaceuticals, Inc) - Market Value to Book Value|Market Value to Book Value Ratio CervoMed Inc. CRVO|ATHE - Market Cap to Net Assets Ratio|Clene Nanomedicine - Market Capitalization to Book Value Ratio|PEPG - Market Capitalization to Book Value Ratio|JUNS: Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Relmada Corp|ANVS (Annovis Bio, Inc.) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Grace Tx GRCE|Market Cap to Net Assets Ratio AIFF (Firefly Neuroscience)|Market Capitalization to Book Value Ratio anewmeds.com (KLTO)|NeuroSense Therapeutics Ltd. - Market Cap to Net Assets Ratio|Market Cap to Book Value Multiple RVPH (Reviva Pharmaceuticals, Inc.)|MetaVia, Inc. - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value neuraxis.com NRXS|HSDT: Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Passage Bio|NEUP (Neuphoria Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Minerva|Market Value to Book Value Ratio Athira Pharma, Inc. (ATHA)|Market Value to Book Value Ratio ADXN (addextherapeutics.com)|Market Value to Book Value Ratio Alzamend Neuro ALZN|Market Capitalization to Book Value Cyclerion Therapeutics Inc. (CYCN)|PTIX - Market Value to Book Value Ratio|KTTA (Pasithea Therapeutics) - Capitalization to Book Value Ratio|cortigent.com (CRGT) - Market Value to Book Value Ratio|avenuetx.com - Market Value to Book Value|BCLI (BrainStorm Cell Therapeutics) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio CARA|Market Value to Book Value Ratio Chromocell Therapeutics Corporation (CHRO)|ELYM - Market-to-Book Ratio|Market Value to Book Value Ratio Intra-Cellular Therapies, Inc. ITCI|LBPH: Capitalization to Book Value Ratio|Marinus Pharmaceuticals, Inc. - Market Capitalization to Book Value Ratio|Market-to-Book Ratio NKGen Biotech Inc|SAGE (Sage Therapeutics, Inc) - Market Cap to Net Assets Ratio|Synaptogenix, Inc (SNPX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Trevena, Inc.|VIGL: Market Value to Book Value|Market Value to Book Value Ratio Anew Medical, Inc. (WENA)|CERE - Market-to-Book Ratio